Draig Therapeutics Launches with $140 Million (107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric…
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
June 03, 2025 01:00 ET | Source: argenx SE June 3, 2025Amsterdam,…
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease…
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease…